Literature DB >> 18471963

BAY 11-7082 induces cell death through NF-kappaB-independent mechanisms in the Ewing's sarcoma family of tumours.

Danielle E White1, Susan A Burchill.   

Abstract

The role of NF-kappaB in the Ewing's sarcoma family of tumours (ESFT) and their response to fenretinide has been investigated. Basal levels of phosphorylated NF-kappaB were low in all ESFT cells. BAY 11-7082 decreased cell viability, which was accompanied by caspase-3 cleavage. This was independent of the increase in reactive oxygen species, p38(MAPK) phosphorylation and expression of NF-kappaB target proteins. NF-kappaB knockdown did not induce death under normal growth conditions, but did reduce TNFalpha-dependent cell survival. Fenretinide-induced apoptosis was independent of NF-kappaB. BAY 11-7082-induced cell death through an NF-kappaB-independent mechanism and enhanced cell death when combined with fenretinide.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18471963     DOI: 10.1016/j.canlet.2008.03.045

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Authors:  Elspeth M Beauchamp; Lymor Ringer; Gülay Bulut; Kamal P Sajwan; Michael D Hall; Yi-Chien Lee; Daniel Peaceman; Metin Ozdemirli; Olga Rodriguez; Tobey J Macdonald; Chris Albanese; Jeffrey A Toretsky; Aykut Uren
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

2.  Lipopolysaccharide-Induced Increase in Intestinal Permeability Is Mediated by TAK-1 Activation of IKK and MLCK/MYLK Gene.

Authors:  Meghali Nighot; Manmeet Rawat; Rana Al-Sadi; Eliseo F Castillo; Prashant Nighot; Thomas Y Ma
Journal:  Am J Pathol       Date:  2019-02-01       Impact factor: 4.307

Review 3.  The NLRP3 Inflammasome Pathway: A Review of Mechanisms and Inhibitors for the Treatment of Inflammatory Diseases.

Authors:  Hallie M Blevins; Yiming Xu; Savannah Biby; Shijun Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-10       Impact factor: 5.702

4.  Minnelide reduces tumor burden in preclinical models of osteosarcoma.

Authors:  Sulagna Banerjee; Venugopal Thayanithy; Veena Sangwan; Tiffany N Mackenzie; Ashok K Saluja; Subbaya Subramanian
Journal:  Cancer Lett       Date:  2013-03-14       Impact factor: 8.679

5.  NFkappaB regulation of platelet function: no nucleus, no genes, no problem?

Authors:  L M Beaulieu; J E Freedman
Journal:  J Thromb Haemost       Date:  2009-06-03       Impact factor: 5.824

6.  Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing's sarcoma family of tumours.

Authors:  D E White; S A Burchill
Journal:  Br J Cancer       Date:  2010-09-28       Impact factor: 7.640

7.  Gene essentiality landscape and druggable oncogenic dependencies in herpesviral primary effusion lymphoma.

Authors:  Mark Manzano; Ajinkya Patil; Alexander Waldrop; Sandeep S Dave; Amir Behdad; Eva Gottwein
Journal:  Nat Commun       Date:  2018-08-15       Impact factor: 14.919

8.  The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases.

Authors:  Navasona Krishnan; Gyula Bencze; Philip Cohen; Nicholas K Tonks
Journal:  FEBS J       Date:  2013-05-09       Impact factor: 5.542

9.  The IKK inhibitor Bay 11-7082 induces cell death independent from inhibition of activation of NFκB transcription factors.

Authors:  Hilka Rauert-Wunderlich; Daniela Siegmund; Eduard Maier; Tina Giner; Ralf C Bargou; Harald Wajant; Thorsten Stühmer
Journal:  PLoS One       Date:  2013-03-20       Impact factor: 3.240

10.  RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-κB pathway, independently of the fusion oncoprotein.

Authors:  Inmaculada Hernandez-Muñoz; Elisabeth Figuerola; Sara Sanchez-Molina; Eva Rodriguez; Ana Isabel Fernández-Mariño; Carlos Pardo-Pastor; María Isabel Bahamonde; José M Fernández-Fernández; Daniel J García-Domínguez; Lourdes Hontecillas-Prieto; Cinzia Lavarino; Angel M Carcaboso; Carmen de Torres; Oscar M Tirado; Enrique de Alava; Jaume Mora
Journal:  Oncotarget       Date:  2016-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.